Before we proceed, I would first like to remind you that during our call today we’ll be making a number of forward-looking statements including statements regarding our and our partners’ research and development programs and plans, including the timing, design and results of clinical trials. The benefits to be derived from and the commercial potential for our product candidates, in each case including pimavanserin, benefits to be derived from changes to clinical trial designs, plans regarding the development of pimavanserin and partnering strategy, and our future expenses and collaboration and grant payments, cash position and stock performance.
These forward looking statements are based on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These factors and other risks associated with our business can be found in our filings made with the SEC, including our annual report on Form 10-K for the year-ended December 31, 2011, and other filings.
You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of today’s date. ACADIA disclaims any obligation to update these forward-looking statements.
I’ll now turn the call over to Uli, our Chief Executive Officer.Uli Hacksell
Thank you, Tom, and good afternoon. Let me first take this opportunity to thank all of you for joining us on today’s conference call. The first half of 2012 was a very important period in our Phase III program with pimavanserin for Parkinson’s Disease Psychosis or PDP, and sets the stage for what we believe will be an exciting and value-driving second half of the year. As you will hear later from Roger, we remain convinced that the optimized study design we have been using in the ongoing pivotal Phase III PDP trial has set enrollment of patients with the desired clinical profile, which should help position this study for success. We look forward to reporting top line results from the Phase III trial this fall and believe that a successful study should significantly increase the value of pimavanserin.